08/20/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Armistead et al.

Serial No.: 09/685,053 Group Art Unit No.: 1624

Filed:

October 6, 2000

Examiner: V. Balasubramanian

For:

KINASE INHIBITORS

Docket No.: A-748E

INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 CFR 1.97(c))

Assistant Commissioner for Patents Washington, D.C. 20231

Sir.

As a means of complying with the duty of disclosure, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but before the mailing date of either.

- a final action under § 1.113 or
- (2) a notice of allowance under § 1.311, whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

a statement as specified in 37 CFR 1.97(e):

OR

EXPRESS MAIL CERTIFICATE

Express Mail med labeling number: EL360688470US

I hereby certify that this paper or tee is being d acting with the United State

ticated above and is addressed to the Ass Sherry L St. Andrew

Printed Name

PATENT APPLICATION

Applicant(s) request(s) consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,

Joseph W. Bulock

Attorney/Agent for Applicant(s)
Registration No.: 37,103

Phone: (805) 447-7966 Date: March 13, 2002

Please send all future correspondence to:

US Patent Operations/ JWB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799